We're Proud to List MeCure Industries' Commercial Paper on AssetBase
MeCure Industries Launches ₦9 Billion Series 4 Commercial Paper on AssetBase
Introduction
At AssetBase, our mission has always been to give you access to high-quality, growth-driven investment opportunities—and today, we’re proud to announce a new addition that perfectly reflects that vision.
We’re pleased to list MeCure Industries Plc’s ₦9 billion Series 4 Commercial Paper on our platform.
This listing allows you to invest in a company that is not only performing financially but also transforming the face of healthcare manufacturing in Nigeria.
About MeCure Industries Plc
MeCure Industries Plc is one of Nigeria’s most prominent pharmaceutical manufacturers, known for its deep-rooted commitment to innovation, high-quality production, and advancing healthcare outcomes through technology.
Established nearly two decades ago, MeCure has consistently pioneeredZrosk Investment Management Limited’s 10% equity stake acquisition further strengthened MeCure's strategic trajectory the pharmaceutical industry, developing cutting-edge formulations, investing in local manufacturing, and bringing science-driven solutions to the Nigerian market. The company made history with the launch of Liquitab Floatcap, Nigeria’s first tablet-in-a-capsule formulation, setting a new benchmark in pharmaceutical product innovation.
In 2024, MeCure transitioned into a Public Limited Company and listed its shares on the Nigerian Exchange (NGX). This bold and strategic move reaffirmed its commitment to transparency, investor trust, and long-term value creation. The listing was met with strong investor confidence, driving share prices upward and elevating the company’s market capitalization to new highs.
MeCure’s operational expansion continues at pace. In Q1 2024, the company installed a state-of-the-art Beta-Lactam plant, securing NAFDAC approval to locally manufacture Amoxicillin-Clavulanic acid (Amoxyclav)—a leading combination antibiotic in a market worth over ₦500 billion. Alongside this, MeCure also completed a corticosteroids production plant to support the treatment of inflammatory conditions, reinforcing its role as a domestic pharmaceutical powerhouse.
In October 2024, Zrosk Investment Management Limited’s 10% equity stake acquisition further strengthened MeCure's strategic trajectory, signaling strong institutional backing and setting the stage for accelerated growth. This investment is helping MeCure optimize its operations, access deeper financial resources, and scale its impact within and beyond Nigeria.
With a proven track record of financial stability, robust governance, and a visionary executive team, MeCure Industries Plc continues to lead the way in shaping the future of pharmaceutical manufacturing in Africa, delivering medicines and lasting value to investors, communities, and the healthcare ecosystem at large.
Recent Developments: New Production Facilities and Strategic Investment
MeCure Industries Plc has been on a steadfast growth trajectory, achieving several significant milestones that position it at the forefront of Nigeria’s pharmaceutical manufacturing sector. One of the key developments in the company’s strategic growth came in October 2023, when MeCure began installing its state-of-the-art Beta-Lactam plant. This facility is dedicated to producing high-demand antibiotics, focusing on Amoxicillin-Clavulanic acid (Amoxyclav)—a drug crucial for treating bacterial infections and with a market size exceeding ₦500 billion. This new plant, which reached completion in Q1 2024, is a testament to MeCure's commitment to localizing production and reducing Nigeria’s dependence on imported medicines.
In a groundbreaking achievement, MeCure became the first local producer of Amoxyclav in Nigeria after receiving approval from the National Agency for Food and Drug Administration and Control (NAFDAC) in April 2024. This milestone marks a turning point in the pharmaceutical industry, as it demonstrates MeCure’s capability to manufacture complex medicines locally, ensuring both supply security and cost reduction in critical health sectors.
Alongside the Beta-Lactam plant, MeCure has also completed the installation of a corticosteroids production plant—a significant addition to its portfolio aimed at addressing inflammatory and autoimmune conditions. This plant is expected to provide MeCure with a robust pipeline for treatment options in a sector with increasing demand, further bolstering the company’s revenue streams and expanding its market reach. With this new facility, MeCure is poised to meet the growing need for these essential medications, ensuring greater access for Nigerian patients and solidifying its leadership in the local pharmaceutical market.
To fuel its ambitious growth plans and expedite its market expansion, MeCure secured a landmark investment in October 2024, when Zrosk Investment Management Limited acquired a 10% equity stake. This strategic investment strengthens MeCure’s financial position and provides valuable capital and advisory support for the company’s expansion plans across Nigeria and the broader West African region. With the backing of Zrosk, MeCure is poised to accelerate its operational efficiency, expand its manufacturing capacity, and extend its reach in key regional markets, ensuring that it remains a competitive force in the rapidly evolving pharmaceutical industry.
These developments underscore MeCure’s dedication to innovation and sustainability in the Nigerian pharmaceutical sector. By consistently advancing its manufacturing capabilities and securing strategic partnerships, MeCure is positioning itself for long-term growth within Nigeria and across the West African sub-region.
Strong Financial Performance
MeCure’s financials reflect its operational strength and strategic discipline. In FY 2024, the company reported:
- Revenue: ₦46.03 billion, a 44.4% increase year-on-year from ₦31.76 billion in 2023.
- Operating Profit: ₦8.28 billion, representing a 36.2% increase from the previous year’s ₦6.08 billion.
An increase in the sale of finished pharmaceutical products and greater operational efficiencies primarily drive this impressive growth. With a stable and experienced executive management team, MeCure continues to deliver consistent value to its shareholders.
Credit Rating and Stability
MeCure Industries Plc holds a short-term rating of A2 by GCR and A1 by Data Pro, reflecting its financial stability and low credit risk profile. These ratings underscore the company’s ability to meet short-term obligations and maintain a strong position in the Nigerian pharmaceutical ecosystem.
Commercial Paper Offering on AssetBase
This Series 4 Commercial Paper is now open for subscription on AssetBase, offering competitive returns for investors looking for short-term, high-yield instruments.
Offering Details:
- Asset Name: MeCure Industries Commercial Paper
- Category: Debt (Commercial Paper)
- Location: Nigeria
- Tenor: 267 days
- Annual Implied Yield: 27.0%
- Gross Expected Yield: 19.75%
- Minimum Subscription: ₦100,000
- Offer Open Date: April 30th, 2025
- Maturity Date: January 26th, 2026
- Total Asset Value on AssetBase: ₦30 million
- Issuer Programme Size: Up to ₦40 billion
- Issuer Target Size (This Series): ₦9 billion
- Withholding Tax: 10%
- Processing Fee: 2%
- Issuer Rating: A2 (GCR), A1 (Data Pro)
- Issuing Institution: Chaka Technologies Limited
Why You Should Invest
MeCure Industries Plc continues to set the standard for innovation, local production, and market leadership in Nigeria’s pharmaceutical sector. With its recent milestones, including establishing the Beta-Lactam and corticosteroids plants, MeCure is addressing critical healthcare needs and driving Nigeria’s pharmaceutical self-sufficiency. The company's strategic focus on local production of high-demand medicines, such as Amoxyclav, ensures that it remains at the forefront of the industry, poised to capitalize on the growing healthcare demands of Nigeria and West Africa.
The successful listing of MeCure on the Nigerian Exchange (NGX), coupled with the recent strategic investment by Zrosk Investment Management, demonstrates the strong investor confidence in the company's prospects. These developments underscore MeCure's ability to scale its operations, expand its market presence, and deliver exceptional value to its stakeholders.
As the company moves forward, its continued investment in advanced manufacturing facilities, cutting-edge product lines, and strategic partnerships will ensure that MeCure remains a key player in transforming Nigeria's healthcare sector. Focusing on delivering high-quality, locally produced medicines and expanding its regional influence, MeCure is poised to meet the healthcare needs of millions, contribute to economic growth, and solidify its position as a leader in the African pharmaceutical landscape.
For investors looking to participate in this exciting phase of MeCure's growth, AssetBase offers an excellent opportunity to invest in their ₦9 billion Series 4 Commercial Paper Issuance. This offers a unique chance to invest in a promising pharmaceutical company with a strong market position and a solid growth trajectory. With an attractive annual implied yield of 27.0%, and a minimum subscription of ₦100,000, this is an investment opportunity you won’t want to miss.
